Bajaj Healthcare announces an acquisition

Total consideration: Rs 10.85 Crores, paid in cash for 100% control of Genrx Pharmaceuticals. ^[1]

Implied EV/EBITDA: Not determinable from the reported information. Genrx’s last reported EBITDA, along with any debt or cash adjustment needed to convert equity purchase consideration into enterprise value, is not disclosed. The mechanical proxy would be:

`EV/EBITDA = Rs 10.85 Crores / Genrx EBITDA`

The NCLT disclosure confirms approval of the acquisition on a going-concern basis and Genrx’s proposed status as a wholly owned subsidiary, but does not state the consideration or Genrx’s EBITDA. ^[2]

Genrx appears complementary mainly as an additional, WHO-GMP-certified formulation platform—not as a wholly new product category or a proven new-market gateway. BHL already had API manufacturing and finished-dose capabilities; Genrx adds a Nashik manufacturing site and capabilities across allopathic formulations, nutraceuticals and natural products. However, the evidence does not identify any new country registrations, customer contracts, tender eligibility, or product approvals transferred to BHL.

How the businesses fit

What regulatory or market access was actually obtained?

• NCLT transaction approval: The NCLT Mumbai Bench approved the acquisition of Genrx on a going-concern basis through its order dated October 13, 2026; Genrx is to become a wholly owned subsidiary of BHL subject to implementation of the order’s terms ^{[4] [2]}. This is a legal and transaction-completion approval, not a product or manufacturing-site marketing authorisation.
• WHO-GMP manufacturing status: Genrx was described as a WHO-GMP-certified manufacturer ^[1]. This could support manufacturing credibility and customer qualification, but the evidence does not establish that the certification is newly granted, that it transfers automatically to BHL, or that BHL previously lacked equivalent certifications.
• No specific new market access is identified: There is no cited evidence of Genrx bringing CDSCO product approvals, USFDA/EMA approvals, country registrations, approved ANDAs, named institutional contracts, or new tender eligibility. BHL already served institutional channels including government healthcare programmes, defence establishments, railway hospitals and employee healthcare systems ^[3]; therefore, the acquisition cannot be characterised on the available evidence as giving BHL a previously absent institutional-market route.

Implication: The acquisition’s demonstrated value is capacity, site infrastructure and formulation breadth, with potential API-to-formulation integration. The regulatory and commercial upside remains conditional: BHL states that the Nashik facility is to be operationalised subject to necessary approvals ^[3]. The current disclosures do not support a stronger claim that Genrx immediately provides BHL with new product registrations or geographic market access.

The NCLT order provides an immediate legal effective date, but not a defined operational-integration deadline. The acquisition was approved on 13 October 2026, and the order is stated to remain effective from that date until any further NCLT order or direction. Genrx is to become a wholly owned subsidiary of Bajaj Healthcare, subject to implementation of the terms specified in the order. ^[2]

Integration timeline

• Legal status: Effective from 13 October 2026, based on the NCLT order date. ^[2]
• Operational integration: No specific completion date or milestone schedule is stated in the disclosed NCLT-order summary. The only earlier public indication was an expectation of 3–6 months, subject to regulatory approvals; that was a third-party report from April 2025 and has not been reaffirmed in the final NCLT disclosure. ^[1]
• Facility readiness: Company material subsequently described the Nashik facility acquired through Genrx as to be operationalised subject to necessary approvals, indicating that legal acquisition and operating readiness are separate steps. ^[3]

Conditions and impact on immediate financial consolidation

The disclosed order summary does not identify a specific condition precedent, penalty, restriction, sanction, or regulatory non-compliance. It records only that:

• Genrx’s status as a wholly owned subsidiary is subject to implementation of the NCLT-order terms. ^[2]
• Bajaj Healthcare will take the necessary actions in accordance with those terms. ^[2]
• The disclosure reports no identified aberration or non-compliance and no penalty, restriction, or sanction imposed by the Tribunal. ^[2]

Implication: The order, as disclosed, does not expressly prohibit immediate consolidation or prescribe a deferred accounting date. However, the filing also does not specify whether all implementation steps have been completed, nor does it state the accounting date from which Genrx’s assets, liabilities, revenue and expenses will be included in Bajaj Healthcare’s consolidated financial statements. Therefore, the key near-term monitorable is the subsequent implementation filing and the next consolidated results—not the NCLT approval alone. The 3–6 month figure should be treated as an earlier operating expectation, not as a binding timeline in the final order.